(Q37328204)

19 August 2017

1 reference

title

Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs). (English)

1 reference

19 August 2017

1

Peter H Wiernik

1 reference

19 August 2017

publication date

19 November 2008

1 reference

Current Treatment Options in Oncology

19 August 2017

published in

1 reference

19 August 2017

volume

10

1 reference

19 August 2017

issue

1-2

1 reference

19 August 2017

page(s)

1-15

1 reference

A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma

19 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11864-008-0077-X

Thromboembolic risk associated with use of angiogenesis inhibitors used for the treatment of cancers

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11864-008-0077-X

Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma

21 January 2018

1 reference

12 December 2020

The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma.

1 reference

12 December 2020

Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma

1 reference

12 December 2020

BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma

1 reference

12 December 2020

An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome

1 reference

12 December 2020

Multiple myeloma--an update on diagnosis and treatment.

1 reference

12 December 2020

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

1 reference

12 December 2020

Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma

1 reference

12 December 2020

Risk of thrombosis with lenalidomide and its prevention with aspirin

1 reference

12 December 2020

lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells

1 reference

12 December 2020

Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia

1 reference

12 December 2020

First thalidomide clinical trial in multiple myeloma: a decade

1 reference

12 December 2020

Thalidomide and lenalidomide: Mechanism-based potential drug combinations

1 reference

12 December 2020

Clarithromycin potentiates glucocorticoid responsiveness in patients with asthma: results of a pilot study

1 reference

12 December 2020

Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure

1 reference

12 December 2020

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group

1 reference

12 December 2020

Azotemia associated with use of lenalidomide in plasma cell dyscrasias

1 reference

12 December 2020

Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells

1 reference

12 December 2020

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study

1 reference

12 December 2020

The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions

1 reference

12 December 2020

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

1 reference

12 December 2020

Frontline treatment of multiple myeloma in elderly patients

1 reference

12 December 2020

Lenalidomide and venous thrombosis in multiple myeloma

1 reference

12 December 2020

Lenalidomide-induced warm autoimmune hemolytic anemia

1 reference

12 December 2020

Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation

1 reference

12 December 2020

The role of lenalidomide in the management of myelodysplasia with del 5q.

1 reference

12 December 2020

Lenalidomide-associated hypothyroidism

1 reference

12 December 2020

Thalidomide for treatment of multiple myeloma: 10 years later

1 reference

12 December 2020

Immunomodulating drugs for chronic lymphocytic leukaemia

1 reference

12 December 2020

Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.

1 reference

12 December 2020

Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.

1 reference

12 December 2020

Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy

1 reference

12 December 2020

Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma

1 reference

12 December 2020

Treatment of follicular non-Hodgkin's lymphoma: the old and the new.

1 reference

12 December 2020

Concurrent B-cell chronic lymphocytic leukemia and multiple myeloma treated successfully with lenalidomide

1 reference

12 December 2020

Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia

1 reference

12 December 2020

Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients

1 reference

12 December 2020

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

1 reference

12 December 2020

The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis

1 reference

12 December 2020

CC-4047 promotes Th1 cell differentiation and reprograms polarized human Th2 cells by enhancing transcription factor T-bet

1 reference

12 December 2020

Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation

1 reference

12 December 2020

The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis

1 reference

12 December 2020

Lenalidomide and its role in the management of multiple myeloma

1 reference

12 December 2020

Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma

1 reference

12 December 2020

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

12 December 2020

The neutropenia induced by the thalidomide analogue CC-4047 in patients with multiple myeloma is associated with an increased percentage of neutrophils bearing CD64

1 reference

12 December 2020

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

1 reference

12 December 2020

Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy?

1 reference

12 December 2020

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

1 reference

12 December 2020

Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis

1 reference

12 December 2020

Treatment of plasma cell dyscrasias with lenalidomide

1 reference

12 December 2020

Thalidomide: mechanisms of action

1 reference

12 December 2020

Targeted treatment and new agents in diffuse large B-cell lymphoma

1 reference

12 December 2020

Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide

1 reference

12 December 2020

Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities

1 reference

12 December 2020

Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL).

1 reference

12 December 2020

Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping

1 reference

12 December 2020

Pathophysiological considerations to thrombophilia in the treatment of multiple myeloma with thalidomide and derivates.

1 reference

12 December 2020

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

1 reference

12 December 2020

Occurrence of myeloma in a chronic lymphocytic leukemia patients after response to differentiation therapy with interleukin-4

1 reference

12 December 2020

Antibiotics directly induce apoptosis in B cell lymphoma cells derived from BALB/c mice.

1 reference

12 December 2020

Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1.

1 reference

12 December 2020

Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial

1 reference

12 December 2020

Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma

1 reference

12 December 2020

Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model

1 reference

12 December 2020

Thalidomide and rituximab in Waldenstrom macroglobulinemia

1 reference

12 December 2020

American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer.

1 reference

12 December 2020

A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma

1 reference

12 December 2020

Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo

1 reference

12 December 2020

Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells

1 reference

12 December 2020

Thalidomide maintenance following high-dose melphalan with autologous stem cell support in myeloma

1 reference

12 December 2020

Lenalidomide in the treatment of multiple myeloma: a review

1 reference

12 December 2020

The thalidomide analogue, CC-4047, induces apoptosis signaling and growth arrest in childhood acute lymphoblastic leukemia cells in vitro and in vivo.

1 reference

12 December 2020

Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone

1 reference

12 December 2020

Immunomodulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesis

1 reference

12 December 2020

Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations

1 reference

12 December 2020

Lenalidomide: a new therapy for multiple myeloma

1 reference

12 December 2020

Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients

1 reference

12 December 2020

Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer.

1 reference

12 December 2020

Complete remission induced by thalidomide in a case of angioimmunoblastic T-cell lymphoma refractory to autologous stem cell transplantation

1 reference

12 December 2020

Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes

1 reference

12 December 2020

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

1 reference

12 December 2020

Lenalidomide-associated tumor flare reaction is manageable in patients with chronic lymphocytic leukemia.

1 reference

12 December 2020

Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study

1 reference

12 December 2020

Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma

1 reference

12 December 2020

Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease

1 reference

12 December 2020

Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells

1 reference

12 December 2020

Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis

1 reference

12 December 2020

Thromboembolic events with lenalidomide-based therapy for multiple myeloma

1 reference

12 December 2020

Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma.

1 reference

12 December 2020

Lenalidomide for the treatment of B-cell malignancies

1 reference

12 December 2020

Thalidomide in multiple myeloma--clinical trials and aspects of drug metabolism and toxicity

1 reference

12 December 2020

Improved survival in multiple myeloma and the impact of novel therapies

1 reference

12 December 2020

A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma

1 reference

12 December 2020

Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma

1 reference

12 December 2020

Thalidomide analogues as anticancer drugs

1 reference

12 December 2020

Novel anti-myeloma agents and angiogenesis.

1 reference

12 December 2020

10.1007/S11864-008-0077-X

Identifiers

DOI

1 reference

19 August 2017

1 reference